SG Americas Securities LLC Raises Stake in LivaNova PLC $LIVN

SG Americas Securities LLC boosted its stake in LivaNova PLC (NASDAQ:LIVN) by 256.6% in the 1st quarter, Holdings Channel reports. The firm owned 86,490 shares of the company’s stock after acquiring an additional 62,233 shares during the quarter. SG Americas Securities LLC’s holdings in LivaNova were worth $5,497,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Hantz Financial Services Inc. boosted its position in shares of LivaNova by 159.9% in the fourth quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after acquiring an additional 267 shares during the period. State of Wyoming bought a new stake in LivaNova during the 2nd quarter worth approximately $31,000. EverSource Wealth Advisors LLC lifted its stake in LivaNova by 998.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after purchasing an additional 639 shares in the last quarter. Quarry LP purchased a new stake in LivaNova in the 3rd quarter worth approximately $36,000. Finally, Covestor Ltd boosted its holdings in LivaNova by 108.6% in the 4th quarter. Covestor Ltd now owns 753 shares of the company’s stock valued at $46,000 after purchasing an additional 392 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

LIVN has been the subject of a number of recent analyst reports. Robert W. Baird reduced their price target on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. KeyCorp lifted their price objective on LivaNova from $83.00 to $92.00 and gave the company an “overweight” rating in a research note on Monday, June 22nd. Barclays boosted their target price on LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 7th. Weiss Ratings upgraded LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research note on Thursday, May 7th. Finally, Mizuho upped their target price on LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. Six research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $80.75.

LivaNova Price Performance

Shares of NASDAQ:LIVN opened at $83.38 on Monday. The company’s fifty day moving average price is $72.20 and its 200-day moving average price is $66.95. The firm has a market capitalization of $4.58 billion, a price-to-earnings ratio of 42.76 and a beta of 0.88. LivaNova PLC has a one year low of $41.01 and a one year high of $83.98. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.11.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.13. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The company had revenue of $362.26 million during the quarter, compared to the consensus estimate of $346.05 million. During the same period in the previous year, the firm posted $0.88 EPS. The firm’s revenue was up 14.3% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, equities research analysts anticipate that LivaNova PLC will post 3.73 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of LivaNova stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the completion of the sale, the director owned 7,228 shares of the company’s stock, valued at $547,521. The trade was a 19.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.35% of the stock is owned by insiders.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.